Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics
CTKB Price/Volume Stats
Current price | $6.80 | 52-week high | $12.31 |
Prev. close | $6.95 | 52-week low | $3.80 |
Day low | $6.52 | Volume | 990,000 |
Day high | $6.99 | Avg. volume | 738,292 |
50-day MA | $8.09 | Dividend yield | N/A |
200-day MA | $7.52 | Market Cap | 889.60M |
CTKB Stock Price Chart Interactive Chart >
CTKB POWR Grades
- CTKB scores best on the Value dimension, with a Value rank ahead of 59.46% of US stocks.
- The strongest trend for CTKB is in Quality, which has been heading up over the past 26 weeks.
- CTKB ranks lowest in Growth; there it ranks in the 19th percentile.
CTKB Stock Summary
- CYTEK BIOSCIENCES INC's stock had its IPO on July 23, 2021, making it an older stock than just 5.26% of US equities in our set.
- The price/operating cash flow metric for CYTEK BIOSCIENCES INC is higher than 99.54% of stocks in our set with a positive cash flow.
- Over the past twelve months, CTKB has reported earnings growth of -6,167.71%, putting it ahead of merely 0.3% of US stocks in our set.
- Stocks that are quantitatively similar to CTKB, based on their financial statements, market capitalization, and price volatility, are SQSP, UPST, NVRO, SPIR, and GENC.
- To check out CYTEK BIOSCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001831915.
CTKB Valuation Summary
- In comparison to the median Healthcare stock, CTKB's price/earnings ratio is 400.17% lower, now standing at -87.5.
- Over the past 30 months, CTKB's price/sales ratio has gone down 19.6.
Below are key valuation metrics over time for CTKB.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CTKB | 2023-12-29 | 6.8 | 3.0 | -87.5 | -80.1 |
CTKB | 2023-12-28 | 7.0 | 3.1 | -90.7 | -83.4 |
CTKB | 2023-12-27 | 7.0 | 3.1 | -90.5 | -83.2 |
CTKB | 2023-12-26 | 7.0 | 3.1 | -91.1 | -83.9 |
CTKB | 2023-12-22 | 7.0 | 3.1 | -91.3 | -84.1 |
CTKB | 2023-12-21 | 6.8 | 3.0 | -88.5 | -81.1 |
CTKB Price Target
For more insight on analysts targets of CTKB, see our CTKB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $27.00 | Average Broker Recommendation | 1.67 (Moderate Buy) |
Cytek BioSciences, Inc. (CTKB) Company Bio
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare ConferenceFREMONT, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. CEO Dr. Wenbin Jiang is scheduled to present and participate in a Q&A session on Thursday, January 11, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentatio |
Insider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 SharesMing Yan, Chief Technology Officer of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company on December 19, 2023, according to a recent SEC Filing. |
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow CytometryNew System Saves Time and Resources, Improves Efficiency and Accuracy Cytek Orion The new Cytek® Orion™ reagent cocktail preparation system simplifies and accelerates laboratory workflow, assures consistent experimental results, saves time and reduces the potential for errors. FREMONT, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the introduction of the Cytek Orion™ reagent cocktail preparation system |
Insider Sell Alert: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences Inc (CTKB)In the realm of stock market movements, insider trading activity is often a significant indicator for investors. |
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare ConferenceFREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Tuesday, November 28th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “ |
CTKB Price Returns
1-mo | -20.09% |
3-mo | -28.42% |
6-mo | 7.42% |
1-year | -28.42% |
3-year | N/A |
5-year | N/A |
YTD | -25.44% |
2023 | -10.68% |
2022 | -37.44% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...